BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11006129)

  • 1. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity.
    Aso T; Yamazaki K; Aigaki T; Kitajima S
    Biochem Biophys Res Commun; 2000 Sep; 276(1):355-61. PubMed ID: 11006129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
    Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
    Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.
    Schoenfeld AR; Davidowitz EJ; Burk RD
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8507-12. PubMed ID: 10900011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ; Ohh M; Moslehi J; Kondo K; Kaelin WG; Welch WJ
    Mol Cell Biol; 2002 Mar; 22(6):1947-60. PubMed ID: 11865071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.
    Adryan B; Decker HJ; Papas TS; Hsu T
    Oncogene; 2000 Jun; 19(24):2803-11. PubMed ID: 10851083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Von Hippel-Lindau disease].
    Shuin T; Ashida S; Yao M; Kanno H
    Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity.
    Lisztwan J; Imbert G; Wirbelauer C; Gstaiger M; Krek W
    Genes Dev; 1999 Jul; 13(14):1822-33. PubMed ID: 10421634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of elongin C sequences required for interaction with the von Hippel-Lindau tumor suppressor protein.
    Takagi Y; Pause A; Conaway RC; Conaway JW
    J Biol Chem; 1997 Oct; 272(43):27444-9. PubMed ID: 9341197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cloning and characterization of the von Hippel-Lindau-like protein.
    Qi H; Gervais ML; Li W; DeCaprio JA; Challis JR; Ohh M
    Mol Cancer Res; 2004 Jan; 2(1):43-52. PubMed ID: 14757845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.
    Kamura T; Brower CS; Conaway RC; Conaway JW
    J Biol Chem; 2002 Aug; 277(33):30388-93. PubMed ID: 12048197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity.
    Lewis MD; Roberts BJ
    Oncogene; 2004 Mar; 23(13):2315-23. PubMed ID: 14691445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.
    Olschwang S; Richard S; Boisson C; Giraud S; Laurent-Puig P; Resche F; Thomas G
    Hum Mutat; 1998; 12(6):424-30. PubMed ID: 9829912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
    Tsuchiya H; Iseda T; Hino O
    Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
    Pastore Y; Jedlickova K; Guan Y; Liu E; Fahner J; Hasle H; Prchal JF; Prchal JT
    Am J Hum Genet; 2003 Aug; 73(2):412-9. PubMed ID: 12844285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.